FDA Accepts Teva's NDA for Once-Monthly Olanzapine Injectable for Schizophrenia
Feb 21, 2026
The FDA has accepted Teva and Medincell's New Drug Application for TEV-'749, a once-monthly subcutaneous olanzapine formulation for schizophrenia treatment that showed no need for post-injection monitoring in Phase 3 trials.